Anonymous
Guest
Anonymous
Guest
Given the most recent news on Ilaris's non-approval vote for gout with regards to safety, isn't there a clear link that the only reason why Novartis is doing such an initiative right now in the market is to pre-selling Ilaris out of label? Isn't that against our CIA and FDA guidance?